Sofinnova Investments’s Celldex Therapeutics CLDX Stock Holding History

Sofinnova Investments’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-547,707	Closed	-$20.3M	–	70
2024 Q2	$20.3M	Sell	547,707 -254,070	-32%	-$9.59M	1.05%	30
2024 Q1	$33.7M	Sell	801,777 -42,231	-5%	-$1.73M	1.87%	20
2023 Q4	$33.5M	Buy	844,008 +419,749	+99%	+$12.3M	1.87%	14
2023 Q3	$11.7M	Buy	424,259 +226,501	+115%	+$7.1M	0.74%	35
2023 Q2	$6.71M	Sell	197,758 -221,639	-53%	-$7.47M	0.44%	36
2023 Q1	$15.1M	Buy	+419,397	New	+$18.1M	0.97%	28
2022 Q3	–	Sell	-48,304	Closed	-$1.3M	–	61
2022 Q2	$1.3M	Buy	+48,304	New	+$1.4M	0.11%	53
2022 Q1	–	Sell	-271,533	Closed	-$10.5M	–	69
2021 Q4	$10.5M	Buy	271,533 +134,501	+98%	+$5.86M	0.61%	42
2021 Q3	$7.4M	Buy	137,032 +2,308	+2%	+$108K	0.44%	46
2021 Q2	$4.5M	Buy	+134,724	New	+$3.7M	0.26%	52

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments's CLDX Position: Q3 2024 in Review

Sofinnova Investments sold out of Celldex Therapeutics (CLDX) in Q3 2024, closing a stake of 547,707 shares — an estimated $20.3M sold.

Sofinnova Investments first reported a position in CLDX in Q2 2021 and held it in 10 quarters. The position peaked at $33.7M in Q1 2024. 176 funds tracked by Wall St. Rank hold CLDX as of Q3 2024.

Sofinnova Investments reported no remaining Celldex Therapeutics position as of Q3 2024 after selling out during the quarter.
Sofinnova Investments sold 547,707 Celldex Therapeutics shares in Q3 2024, an estimated $20.3M.
Sofinnova Investments first reported a position in Celldex Therapeutics in Q2 2021 and held it in 10 quarters.
Sofinnova Investments's Celldex Therapeutics position peaked at $33.7M in Q1 2024.
176 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2024.

Based on Sofinnova Investments's 13F filing for Q3 2024, filed 13 Nov 2024.